


PANEL A



PANEL B

Fig. 1




Fig. 2






Fig. 3

NBN1 ChAT bioassay



TH+ cell number at DIV 7



Figs. 4A, 4B and 4C




Fig. 5A and 5B


TH-ir cells per culture

Fig. 5C




Fig. 6




Fig. 7

Alignment of Neublastin primers used in Rapid-Screen with
homologous regions in other GDNF ligands

5' -C CTG GCC AGC CTA CTG GG-3'	SEQ ID No 17
G CTG GCC CGG CTG CAG GG	persephin
G CTG CGA CGA CTG CGC CA	neurturin
A TTG AAA AAC TTA TCC AG	GDNF

5' -AA GGA GAC CGC	TTC GTA GCG-3'	SEQ ID No 18
TA GGC CAC GTC	GGT GTA GCG	persephin
AA GGA CAC CTC GTC	CTC GTA GGC	neurturin
AA CGA CAG GTC ATC	ATC AAA GGC	GDNF

conserved nucleotides shown in bold

Fig. 8




Fig. 9

11/16




Fig. 10

Relative Chemiluminescence Units (R.U.)






Fig. 11



1. Control medium stained with R30 anti-peptide antibody
2. Neublazin containing conditioned medium stained with R30 anti-peptide antibody
3. Control medium stained with R31 anti-peptide antibody
4. Neublazin containing conditioned medium stained with R31 anti-peptide antibody

Fig. 12




Extraction of neublastin by affinity-binding on RETL3-Ig

Lane 1: bound from CHO control conditioned media

Lane 2: bound from neublastin overexpressing CHO conditioned media


Fig. 13



Neublastin Syngene

NcoI (318)					
316	TACCATGGCT	GGAGGACCGG	GATCTCGTGC	TCGTGCAGCA	GGAGCACGTG
	ATCCTACCGA	CCTCCTGGCC	CTAGAGCACG	AGCACGTCGT	CCTCGTGCAC
	1► M A	G G P	G S R A	R A A	G A R
					G C R L
376	GCGTTCTCAA	CTAGTGCCGG	TGCGTGCACT	CGGACTGGGA	CACCGTTCCG
	CGCAAGAGTT	GATCACGGCC	ACGCACGTGA	GCCTGACCCT	GTGGCAAGGC
	19► R S Q	L V P	V R A L	G L G	H R S
					D E L V
436	ACGTTTTTCGT	TTTTGTTCAG	GATCTTGTCG	TCGTGCACGT	TCTCCGCATG
	TGCAAAAGCA	AAAACAAGTC	CTAGAACAGC	AGCACGTGCA	AGAGGCGTAC
	39► R F R	F C S	G S C R	R A R	S P H
					D L S L
496	AGCATCTCTA	CTAGGAGCCG	GAGCACTAAG	ACCGCCGCCG	GGATCTAGAC
	TCGTAGAGAT	GATCCTCGGC	CTCGTGATTC	TGGCGGCGGC	CCTAGATCTG
	59► A S L	L G A	G A L R	P P P	G S R
					P V S Q
556	ACCTTGTTGT	AGACCTACTA	GATACGAAGC	AGTATCTTTC	ATGGACGTAA
	TGGAACAACA	TCTGGATGAT	CTATGCTTCG	TCATAGAAAG	TACCTGCATT
	79► P C C	R P T	R Y E A	V S F	M D V
					N S T W
BamHI (671)					
616	GAGAACCGTA	GATAGACTAT	CTGCAACCGC	ATGTGGCTGT	CTAGGATGAT
	CTCTTGGCAT	CTATCTGATA	GACGTTGGCG	TACACCGACA	GATCCTACTA
	99► R T V	D R L	S A T A	C G C	L G . . .
676	CGGCT				
	GCCGA				

Fig. 14



HisNeublastin

XhoI (340)

301 TACCATGGGC CATCATCATC ATCATCATCA TCATCATCAC TCGAGCGGCC ATATCGACGA
 ATCTTACCCG GTAGTAGTAG TAGTAGTAGT AGTAGTAGTG AGCTCGCCGG TATAGCTGCT
 1 ▶ M G H H H H H H H H S S G H I D D

361 CGACGACAAG GCTGGAGGAC CGGGATCTCG TGCTCGTGCA GCAGGAGCAC GTGGCTGTCC
 SCTGCTGTTC CGACCTCCTG GCCCTAGAGC ACGAGCACGT CGTCCTCGTG CACCGACAGC
 19 ▶ D D K A G G P G S R A R A A G A R G C R

421 TCTGCGTTCT CAACTAGTGC CGGTGCGTGC ACTCGGACTG GGACACCGTT CCGACGAACT
 AGACGCAAGA GTTGATCACG GCCACGCACG TGAGCCTGAC CCTGTGGCAA GGCTGCTTGA
 39 ▶ L R S Q L V P V R A L G L G H R S D E L

481 AGTACGTTTT CGTTTTTGTT CAGGATCTTG TCGTCGTGCA CGTTCTCCGC ATGATCTATC
 TCATGCAAAA GCAAAAACAA GTCCTAGAAC AGCAGCACGT GCAAGAGGCG TACTAGATAG
 59 ▶ V R F R F C S G S C R R A R S P H D L S

541 TCTAGCATCT CTACTAGGAG CCGGAGCACT AAGACCGCCG CCGGGATCTA GACCTGTATC
 AGATCGTAGA GATGATCCTC GGCCTCGTGA TTCTGGCGGC GGCCCTAGAT CTGGACATAG
 79 ▶ L A S L L G A G A L R P P P G S R P V S

601 TCAACCTTGT TGTAGACCTA CTAGATACGA AGCAGTATCT TTCATGGACG TAAACTCTAC
 AGTTGGAACA ACATCTGGAT GATCTATGCT TCGTCATAGA AAGTACCTGC ATTTGAGATG
 99 ▶ Q P C C R P T R Y E A V S F M D V N S T

661 ATGGAGAACC GTAGATAGAC TATCTGCAAC CGCATGTGGC TGTCTAGGAT GATAATAGGG
 TACCTCTTGG CATCTATCTG ATAGACGTTG GCGTACACCG ACAGATCCTA CTATTATCCC
 119 ▶ W R T V D R L S A T A C G C L G . .

721 ATCCGGCTGC TAACAAAGCC CG
 TAGGCCGACG ATTGTTTCGG GC

BamHI (719)

Fig. 15